William S. Dalton, Founder and CEO of M2Gen, Elected to The Leukemia & Lymphoma Society National Board of Directors
Contact: Andrea Greif
Tel: (914) 821-8958
Cell: (914) 772-3027
William S. Dalton, Founder and CEO of M2Gen, Elected to The Leukemia &
Lymphoma Society National Board of Directors
White Plains, N.Y. (May 15, 2014) - William S. Dalton, PhD., M.D., founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center, has been elected to the national board of directors of The Leukemia & Lymphoma Society (LLS), effective July 1, 2014. His term will run through June 30, 2017.
Dr. Dalton is the past president, CEO & center director of Moffitt Cancer Center. Prior to that role, Dr. Dalton was dean of the University of Arizona College of Medicine.
He is interested in the development of personalized cancer care and patient-centered outcomes research. Dr. Dalton's basic and translation research interests focus on molecular mechanisms of drug resistance and drug discovery in hematologic malignancies. He has more than 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.